Afatinib

Known as: (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide, 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-, Afatinibum 
An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
INTRODUCTION Afatinib is an effective first-line treatment in patients with epidermal growth factor receptor (EGFR)-mutated non… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
UNLABELLED EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib) develop acquired resistance… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Human epidermal growth factor receptor (HER)2/neu kinase domain mutations are found in approximately 1-4% of lung adenocarcinomas… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
EGF receptor (EGFR)-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKI). The… (More)
  • table 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
7525^ Background: Despite initial responses to reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
Is this relevant?